Business Overview: Radnostix, Inc. (NASDAQ: INIS)

---

Executive Summary

Radnostix, Inc. — known for three decades as International Isotopes Inc. until its December 2025 name change — is a small, diversified radioisotope and radiopharmaceutical company based in Idaho Falls, Idaho. Founded in 1995, it manufactures and sells sealed radioactive sources, calibration standards, and nuclear medicine products to hospitals, imaging-equipment makers, industrial users, and research labs worldwide.

The company matters less for its roughly $13 million in annual revenue than for the breadth of niches it occupies in the U.S. radioisotope supply chain: it is one of only a handful of domestic suppliers of generic sodium iodide I-131, one of the few global sources of cobalt-60 recycling, and the maker of SPECT/PET calibration standards used across the nuclear medicine imaging industry through its RadQual subsidiary. Its FY2025 rebrand to Radnostix signals a strategic pivot toward medical devices and theranostics, away from its dormant Fluorine/depleted-uranium business.

---

1. Core Business Model & How They Work

Radnostix operates as a vertically specialized nuclear materials and devices company, selling directly to end customers (some of whom double as distributors) across five related but distinct product lines.

[ Isotope Production / Sourcing ] ➡️ [ NRC-Licensed Processing & Packaging ] ➡️ [ Theranostics / Cobalt / Calibration / Device Products ] ➡️ [ Hospitals, Imaging OEMs, Industrial & Research Customers ]

Key Operational Drivers

1. Regulatory moat via licensing: operations require NRC licenses, FDA registration for certain products, and DOT authorization for radioactive transport — a high, slow-to-replicate regulatory bar for new entrants.
2. Domestic supply-security positioning: the company markets itself as a U.S.-based alternative to government-run foreign isotope producers, an argument that carries extra weight amid geopolitical supply concerns.
3. Diversification across five lines: theranostics, cobalt, calibration/reference standards, medical devices, and (dormant) fluorine products spread risk across different end markets.
4. Recent pivot to medical devices: the EasyFill capsule system (targeted Q3 2026) and acquired AMICI lung-ventilation products sold through its RadVent subsidiary represent a new, higher-margin growth avenue.

---

2. Business Segments

┌────────────────────────────────────────────┐
│              Radnostix, Inc.                │
└───────────────┬──────────────────────────┘
                     │
   ┌─────────┬───────┼────────┬──────────┐
   ▼         ▼       ▼        ▼          ▼
Theranostics Cobalt Calibration Medical  Fluorine
 Products    Products & Reference Devices  Products
                       Products           (dormant)

1. Theranostics Products — FDA-approved generic sodium iodide I-131, radiopharmaceutical APIs, and radiochemicals; the company's historical core.
2. Cobalt Products — Cobalt-60 sealed sources for radiation therapy and industrial irradiation, plus source recycling services.
3. Calibration & Reference Products — sealed-source calibration standards for SPECT/PET imaging and lab equipment, sold largely through the RadQual subsidiary.
4. Medical Devices — early-stage, including the EasyFill capsule-filling system and AMICI lung-ventilation products sold through RadVent; currently generates revenue mostly from reselling third-party products.
5. Fluorine Products — dormant since 2013, tied to a planned depleted-uranium de-conversion facility; a planned sale of these assets to American Fuel Resources (AFR) was mutually terminated in March 2026, returning the assets to the company.

---

3. Product Portfolio

---

4. Competitive Landscape

• Theranostics (I-131): competes with Jubilant DraxImage, a larger established supplier.
• Calibration products: competes with Eckert & Ziegler and, in limited markets, Epsilon Radioactive Sources.
• Cobalt-60: competes with Nordion, the dominant global cobalt-60 supplier, as well as government-affiliated producers such as NTP (South Africa), BRIT (India), CIRC (China), and Rosatom (Russia), which tend to compete primarily in their home markets.

Radnostix's pitch across all of these lines is domestic production and supply-chain security rather than scale — it is consistently smaller than its named private-sector competitors.

---

5. Strategic Strengths & Risks

Strengths

• NRC/FDA/DOT regulatory licensing creates real barriers to new-entrant competition.
• Diversified across five product lines, limiting single-point failure.
• Domestic, U.S.-based production is a genuine differentiator against foreign state-affiliated suppliers, especially for cobalt-60 and I-131.

Risks

• Revenue decline: FY2025 revenue fell 6% year over year, and the company swung from a small operating profit in FY2024 to an operating loss in FY2025.
• Customer concentration: the three largest customers represented 31% of 2025 gross revenue.
• Execution risk on the pivot: the December 2025 rename to Radnostix and the push into medical devices (EasyFill, RadVent) are unproven; the EasyFill launch has already slipped toward Q3 2026.
• Deep accumulated deficit: $128.2 million as of year-end 2025, reflecting three decades of cumulative losses.
• Terminated asset sale: the failed divestiture of the dormant Fluorine/DUF6 assets to AFR leaves that non-core, non-revenue-generating business back on the balance sheet.

---

6. Financial Overview

---

7. Summary Conclusion

Radnostix occupies real, regulation-protected niches in the U.S. radioisotope supply chain — generic I-131, cobalt-60 recycling, and SPECT/PET calibration standards — that larger pharmaceutical and industrial players have little incentive to enter. That regulatory moat, however, has not translated into growth: revenue and margins both slipped in FY2025, and the company's new identity rests on unproven medical-device bets (EasyFill, RadVent) that have yet to generate meaningful revenue. The biggest forward question is whether the rebrand and device pivot can reverse the top-line decline before the company's multi-decade accumulated deficit becomes a bigger constraint on its ability to invest.